PCI Biotech Holding ASA (OSL:PCIB) OCF Margin %: 0.00% (As of Jun. 2025)


OSL:PCIB PCI Biotech Holding ASA OSL:PCIB
6 GF Score
Price kr0.12
! 1 Warning Sign
View Full Analysis

What is PCI Biotech Holding ASA OCF Margin %?

PCI Biotech Holding ASA OSL:PCIB -12.21% 6 OCF Margin % is 0.00% as of Jun. 2025. GuruFocus rates OSL:PCIB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. PCI Biotech Holding ASA's Cash Flow from Operations for the six months ended in Jun. 2025 was kr-12.53 Mil. PCI Biotech Holding ASA's Revenue for the six months ended in Jun. 2025 was kr0.00 Mil. Therefore, PCI Biotech Holding ASA's OCF Margin % for the quarter that ended in Jun. 2025 was 0.00%.

As of today, PCI Biotech Holding ASA's current OCF Yield % is -588.39%.

The historical rank and industry rank for PCI Biotech Holding ASA's OCF Margin % or its related term are showing as below:


OSL:PCIB's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.71
* Ranked among companies with meaningful OCF Margin % only.

PCI Biotech Holding ASA OCF Margin % Related Terms

PCI Biotech Holding ASA OCF Margin % Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA OCF Margin % Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PCI Biotech Holding ASA Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSL:PCIB
6GF Score
PCI Biotech Holding ASA OSL:PCIB
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PCI Biotech Holding ASA OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

PCI Biotech Holding ASA's OCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-13.758/0
= %

PCI Biotech Holding ASA's OCF Margin for the quarter that ended in Jun. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=-12.528/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
PCI Biotech Holding ASA (OSL:PCIB) has a OCF Margin % of 0.00% as of Jun. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's OCF Margin % too high?
PCI Biotech Holding ASA's current OCF Margin % is 0.00%. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does PCI Biotech Holding ASA's OCF Margin % compare to VRTX and REGN?
PCI Biotech Holding ASA's OCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on PCI Biotech Holding ASA and its competitors. PCI Biotech Holding ASA's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (OSL:PCIB) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current OCF Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
6GF Score

Get the complete analysis for OSL:PCIB

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12
Price